Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Quarterly results
|
|
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"Deferred Prosecution Agreement",
"TEVA SETTLES PRICE FIXING CHARGES WITH U.S. DOJ TEL AVIV, Israel & PARSIPPANY, N.J, August 21, 2023 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , has reached a deferred prosecution agreement with the U.S. Department of Justice to settle the criminal price-fixing charges brought against Teva in 2020. Under the DPA, which will allow Teva to avoid mandatory exclusion from participation in U.S. federal health care programs, Teva will pay a fine of $225 million over five years, with $22.5 million due each year from 2024 through 2027, and $135 million due in 2028. The Company has also agreed to donate $50 million worth of two generic products , to humanitarian organizations, and to divest one additional generic product to a third-party buyer. Teva admits in th..." |
|
| 08/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 06/09/2023 |
SC 13G/A
| Capital Research Global Investors reports a 0% stake in Teva Pharmaceutical Industries Ltd. |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 05/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/24/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Fourth Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent",
"Fourth Supplemental Senior Indenture, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee",
"Opinion of Tulchinsky Marciano Cohen Levitski & Co. (Israeli law)",
"Opinion of Kirkland & Ellis LLP (New York law)",
"Opinion of Van Doorne N.V. (Dutch law)" |
|
| 03/03/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among the Issuers, the Company, Citigroup Global Markets Europe AG, Citigroup Global Markets Inc., Goldman Sachs Bank Europe SE, Mizuho Securities Europe GMBH, Mizuho Securities USA LLC, MUFG Securities (Europe) N.V., MUFG Securities Americas Inc. and PNC Capital Markets LLC as representatives for the underwriters named in Schedule 1 annexed thereto",
"Proceeds to Repay Existing Debt" |
|
| 03/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/01/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 02/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/08/2023 |
F-6EF
| Form F-6EF - Registration of American Depository Receipt shares, immediately effective: |
| 02/08/2023 |
8-K
| Quarterly results |
| 11/21/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/26/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 05/25/2022 |
SD
| Form SD - Specialized disclosure report: |
| 05/03/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/03/2022 |
8-K
| Quarterly results |
| 04/13/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|